<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122884</url>
  </required_header>
  <id_info>
    <org_study_id>SI 111/2021</org_study_id>
    <nct_id>NCT05122884</nct_id>
  </id_info>
  <brief_title>Milrinone Versus Placebo in Patients With Septic Shock</brief_title>
  <official_title>Effect of Milrinone Versus Placebo on Hemodynamics in Patients With Septic Shock; Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is one of the most serious healthcare problems, worldwide, and financial burdens.&#xD;
&#xD;
      The overall mortality of severe sepsis/septic shock was 44.5-52.6%. A common cause of death&#xD;
      is refractory shock and multi-organ failure. Myocardial dysfunction is a relatively common&#xD;
      complication of septic shock. This causes a decrease in the amount of cardiac output,&#xD;
      resulting in insufficient blood supply to the organ and multi-organ failure and lead to death&#xD;
      Early goal-directed therapy began to use dobutamine in patients with septic shock Sepsis&#xD;
      Survival Campaign Guideline 2016 recommended drug is dobutamine and an alternative drug is&#xD;
      milrinone in septic shock patients with clinical signs of poor tissue perfusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to several studies, the use of dobutamine increases the amount of cardiac output&#xD;
      but it has also been reported to increase mortality rates too. There are few studies of&#xD;
      milrinone in patients with septic shock.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Pharmacist who does not involve in patient enrollment nor treatment will prepared milrinone or placebo in the identical container, before the study drug will be given to patients, according to their treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The change of cardiac output from baseline (before study drug administration) to 6 hours (during study administration)</measure>
    <time_frame>upto 24 hours</time_frame>
    <description>by echocardiogram or Pulse contour analysis or Thermodilution technique from pulmonary artery catheter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit (ICU) mortality</measure>
    <time_frame>upto 120 days</time_frame>
    <description>Proportion of participant who die during ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>upto 120 days</time_frame>
    <description>Proportion of participant who die during hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>upto 28 days</time_frame>
    <description>Proportion of participant who die during 28 days after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of vasopressor after intervention</measure>
    <time_frame>upto 7 days</time_frame>
    <description>present as vasopressor equivalent dose compare before and after intervention, and percent of decrease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate clearance</measure>
    <time_frame>upto 7 days</time_frame>
    <description>lactate level after and before intervention and percent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilator free day</measure>
    <time_frame>upto 28 days</time_frame>
    <description>day of the patient does not use mechanical ventilator during admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracorporeal membrane oxygenation (ECMO) or Renal replacement therapy (RRT)</measure>
    <time_frame>upto 28 days</time_frame>
    <description>incident of initial ECMO or RRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident of tachyarrhythmia</measure>
    <time_frame>upto 28 days</time_frame>
    <description>Incident of ventricular tachycardia, ventricular fibrillation, Atrial fibrillation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Septic Shock</condition>
  <condition>Cardiac Output</condition>
  <arm_group>
    <arm_group_label>Milrinone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The pharmacist prepares milrinone 20 mg with normal saline solution (NSS) 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours. The doctor performs Echocardiogram before start Milrinone, during infusion, and after 12 hours from stop Milrinone. Other medications or interventions were used or not used depending on own doctor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The pharmacist uses 100 ml of NSS, packed out in the same format, dose, and administration of the drug were exactly the same as in the milrinone group. The doctor performs Echocardiogram same time as the milrinone group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone</intervention_name>
    <description>Prepare milrinone 20 mg with NSS 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours.</description>
    <arm_group_label>Milrinone group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Primacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years old&#xD;
&#xD;
          -  Diagnosis Septic Shock from the definition of SEPSIS III in intensive care unit at&#xD;
             Siriraj hospital and Hat-Yai hospital&#xD;
&#xD;
          -  Receive fluid resuscitation at least 30 ml/kg and/or Vasopressor until mean arterial&#xD;
             pressure ≥ 65 mmHg&#xD;
&#xD;
          -  Persistence lactate &gt;2mmol/L at 6th hour after resuscitation&#xD;
&#xD;
          -  Urine output &lt; 0.5 ml/kg at 6th hour after resuscitation&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt; 40 %&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic kidney disease stage 5 and denied renal replacement therapy&#xD;
&#xD;
          -  Life-threatening tachyarrhythmia before enrolled e.g. Ventricular tachycardia,&#xD;
             Ventricular fibrillation&#xD;
&#xD;
          -  Patient sign do-not-resuscitation and terminally ill&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Surat Tongyoo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Surat Tongyoo, Doctor</last_name>
    <phone>+6624198534</phone>
    <email>surat_Ty@yahoo.co.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suratee Chobngam, Doctor</last_name>
    <phone>+66807155065</phone>
    <email>areefsu123@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hat Yai Hospital</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chutima Jiranakorn, doctor</last_name>
      <phone>+66815993377</phone>
      <email>waitfor027@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Surat Tongyoo, MD</last_name>
      <phone>+6624198534</phone>
      <email>surat_Ty@yahoo.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Milrinone</keyword>
  <keyword>Septic shock</keyword>
  <keyword>Cardiac output</keyword>
  <keyword>Poor tissue perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milrinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymous identification data will be prepared per request, after study publication 6 months.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>6 months post study publication</ipd_time_frame>
    <ipd_access_criteria>Request to principal investigation, after protocal approval from ethical committee.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

